Article Details
Retrieved on: 2024-02-20 11:17:20
Tags for this article:
Click the tags to see associated articles and topics
Summary
Morningstar reduced Tilray's price target, citing Canada's crowded cannabis market, regulatory challenges, and competition from illicit markets affecting the potential profitability within the medical cannabis sector. This impacts the broader pharmaceutical and cannabis industries amidst the 'Green Rush'.
Article found on: www.greenmarketreport.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here